Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
We have sought to identify a high-capacity transport system that mediates transcytosis of proteins from the blood to the brain. The 39 kDa receptor-associated protein (RAP) functions as a specialized endoplasmic reticulum chaperone assisting in the folding and trafficking of members of the low-density lipoprotein (LDL) receptor family. RAP efficiently binds to these receptors and antagonizes binding of other ligands. Previous studies have shown that two large members of the LDL receptor family, LDL receptor-related protein 1 (LRP1) and LDL receptor-related protein 2 (LRP2 or megalin), possess the ability to mediate transcytosis of ligands across the brain capillary endothelium. Here, we tested whether blood-borne RAP crosses the blood-brain barrier (BBB) by LRP1- or megalin-mediated transport by studying the pharmacokinetics of [125I]-RAP transport into the brain in intact mice and across cell monolayers in vitro. Our results show that [125I]-RAP is relatively stable in blood for 30 minutes and has a mean influx constant of 0.62±0.08 μl/g-minute from blood to brain. In situ brain perfusion in blood-free buffer shows that transport of [125I]-RAP across the BBB is a saturable process. Capillary depletion of brain homogenates indicates that 70% of [125I]-RAP is localized in the parenchyma rather than in the vasculature of the brain. Results of transport in stably transfected MDCK cells are consistent with the hypothesis that megalin mediates most of the apical-to-basolateral transport across polarized epithelial cells. The inhibition of [125I]-RAP influx by excess RAP and the involvement of megalin indicate the presence of a saturable transport system at the BBB. The higher permeability of RAP compared with that of melanotransferrin and transferrin show that the LRP receptor is a high capacity transport system. These studies suggest that RAP may provide a novel means of protein-based drug delivery to the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“One of the RAP receptors, LRP1, is abundantly expressed in brain microvessels in young mice (Shibata et al., 2000).”
BackgroundZlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430
Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ
Pan, W., & Kastin, A. J. (2000) · Neuroendocrinology · doi:10.1159/000054584 · Cited by 185
Self-citation
Cited by
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
“Receptor-associated protein (RAP) participates in the folding and trafficking of LRP1 and LRP2 ( 68 ).”
BackgroundInfluentialIdentification and Design of Peptides as a New Drug Delivery System for the Brain
Demeule, M., Régina, A., Ché, C., Poirier, J., Nguyen, T., Gabathuler, R., Castaigne, J.-P., & Béliveau, R. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131318 · Cited by 462
Pardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller-Salvia, B., Sánchez-Navarro, M., Giralt, E., & Teixidó, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 442
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.044 · Cited by 384
de Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
“…can also transport several ligands transcellularly across the blood–brain barrier (BBB) including Ab (Shibata et al. 2000; Deane et al. 2004a), RAP (Pan et al. 2004), tissue plasminogen activator (Benchenane et al. 2005), lipid free and lipidated apoE2 and apoE3, and apoE2 and apoE3 complexes…”
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Georgieva, J., Hoekstra, D., & Zuhorn, I. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6040557 · Cited by 211
“Low-density lipoprotein receptor-related protein (LRP) 1 (alpha-2-macroglobulin receptor) and 2 (Megalin) are other members of the LDL receptor family that are widely studied for their ability to transport multiple ligands across the BBB. Well-characterized are the LRP-dependent endothelial transport of lactoferrin [8…”
BackgroundPhase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
LDL Receptor–Related Protein-1
Gonias, S. L., & Campana, W. M. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.029 · Cited by 175
Wang, D., El-Amouri, S. S., Dai, M., Kuan, C.-Y., Hui, D. Y., Brady, R. O., & Pan, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222742110 · Cited by 159
“The receptor-associated protein (RAP), an antagonist as well as a ligand for both LRP1 andVLDLR, has been shown to have higher permeability than transferrin in crossing the BBB (13), suggesting that these lipoprotein receptors may be an efficient target for delivery of therapeutic agents across the BBB.”
BackgroundPardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152
Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Ito, S., Ueno, T., Ohtsuki, S., & Terasaki, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06708.x · Cited by 48
Self-citation
Metadata
- Authors
- Pan, W., Kastin, A. J., Zankel, T. C., van Kerkhof, P., Terasaki, T., & Bu, G.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2004-10-01
- Volume
- 117
- Issue
- 21
- Pages
- 5071-5078
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W1981550112
- Cited by
- 153
- References
- 3
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.